

# Craig D Seaman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4853655/publications.pdf>

Version: 2024-02-01

20  
papers

269  
citations

1039880

9  
h-index

940416

16  
g-index

20  
all docs

20  
docs citations

20  
times ranked

434  
citing authors

#	ARTICLE	IF	CITATIONS
1	Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. <i>Haemophilia</i> , 2020, 26, 41-46.	1.0	59
2	Venous thromboembolism in pregnant women with sickle cell disease: A retrospective database analysis. <i>Thrombosis Research</i> , 2014, 134, 1249-1252.	0.8	41
3	Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: A U.S. perspective. <i>Thrombosis Research</i> , 2013, 132, 647-651.	0.8	35
4	Emicizumab use in major orthopedic surgery. <i>Blood Advances</i> , 2019, 3, 1722-1724.	2.5	34
5	Association of von Willebrand factor deficiency with prevalent cardiovascular disease and asymptomatic carotid atherosclerosis: The Atherosclerosis Risk in Communities Study. <i>Thrombosis Research</i> , 2016, 144, 236-238.	0.8	13
6	A case of acquired haemophilia A in a 70-year-old post COVID-19 vaccine. <i>Haemophilia</i> , 2022, 28, .	1.0	13
7	Prevalence and Risk Factors Associated With Hypertension in von Willebrand Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 93-99.	0.7	11
8	The Association of Aging With Von Willebrand Factor Levels and Bleeding Risk in Type 1 Von Willebrand Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 434-438.	0.7	10
9	Feasibility of the Von Willebrand disease PREVENT trial. <i>Thrombosis Research</i> , 2017, 156, 8-13.	0.8	9
10	Prevalence and Risk Factors Associated With Hypertension in Hemophilia: Cross-Sectional Analysis of a National Discharge Register. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 871-875.	0.7	9
11	The Effect of Age on von Willebrand Factor and Bleeding Symptoms in von Willebrand Disease. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1159-1165.	1.8	9
12	Hemophilia A (Factor VIII Deficiency). <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1117-1129.	0.9	7
13	Sequential bypassing agents during major orthopedic surgery: a new approach to hemostasis. <i>Blood Advances</i> , 2017, 1, 1309-1311.	2.5	4
14	Periprocedural management of von Willebrand disease: An institutional experience. <i>Haemophilia</i> , 2019, 25, e199-e203.	1.0	3
15	Unfractionated heparin in acute chest syndrome: a pilot feasibility randomized controlled trial of unfractionated heparin vs. standard of care in acute chest syndrome. <i>Pilot and Feasibility Studies</i> , 2020, 6, 174.	0.5	3
16	Quality of periprocedural care in patients with von Willebrand disease. <i>Haemophilia</i> , 2021, 27, 830-836.	1.0	3
17	The Effects of Aging on Von Willebrand Factor Levels and Bleeding Risk in Type 1 Von Willebrand Disease. <i>Blood</i> , 2016, 128, 2584-2584.	0.6	3
18	Factor VIII concentrate dosing with lean body mass, ideal body weight and total body weight in overweight and obesity: A randomized, controlled, open-label, 3A–A3 crossover trial. <i>Haemophilia</i> , 2021, 27, 351-357.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Cost Effectiveness of Rivaroxaban Versus Warfarin for the Prevention of Recurrent Venous Thromboembolism.. Blood, 2012, 120, 3177-3177.	0.6	1
20	Thrombin Generation and Bleeding in Hemophilia Inhibitor Patients during Immune Tolerance Induction. Blood, 2014, 124, 1514-1514.	0.6	1